The battle for dominance in the weight loss pharmaceutical market has intensified as Eli Lilly’s injectable drug Mounjaro gains significant ground against rival Novo Nordisk’s Wegovy, causing the latter’s stock prices to decline substantially. The frenzy surrounding Novo Nordisk’s diabetes injection Ozempic, which had been marketed as a miracle weight loss solution by celebrities worldwide, … Continue reading Obesity drugs fuel stock market war as Ozempic set to join GHS